Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Europäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie

Hadaschik, Eva, Eming, Rüdiger, French, Lars E., Girolomoni, Giampiero, Hertl, Michael, Jolles, Stephen, Karpati, Sarolta, Steinbrink, Kerstin, Stingl, Georg, Volc-Platzer, Beatrix, Zillikens, Detlef and Enk, Alexander 2020. Europäische Leitlinien (S1) für die Verwendung von hoch dosierten intravenösen Immunglobulinen in der Dermatologie. Hautarzt 71 , pp. 542-552. 10.1007/s00105-020-04610-6

[thumbnail of Hadaschik2020_Article_EuropäischeLeitlinienS1FürDieV.pdf] PDF - Published Version
Available under License Creative Commons Attribution.

Download (0B)


Background and objectivesTreatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe cases, the use of immunoglobulin is not generally based on data from randomized controlled trials usually required for evidence-based medicine. Since the indications for the use of IVIg are rare, it is unlikely that such studies will be available in the foreseeable future. Because first-line use is limited by the high costs of IVIg, the first clinical guidelines on the use of IVIg in dermatological conditions were established in 2008 and renewed in 2011.MethodsThe European guidelines presented here were prepared by a panel of experts nominated by the European Dermatology Forum (EDF) and European Academy of Dermatology and Venereology (EADV). The guidelines were developed to update the indications for treatment currently considered effective and to summarize the evidence for the use of IVIg in dermatological autoimmune diseases and TEN.Results and conclusionThe current guidelines represent consensual expert opinions and definitions on the use of IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Language other than English: German
Publisher: Springer Verlag (Germany)
ISSN: 0017-8470
Date of First Compliant Deposit: 19 June 2020
Last Modified: 02 Jul 2020 10:02

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics